Mirna Therapeutics Inc Stock Nasdaq
Equities
US60470J1034
Biotechnology & Medical Research
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 22.13M |
---|---|---|---|---|---|
Net income 2024 * | -22M | Net income 2025 * | -11M | EV / Sales 2024 * | - |
Net cash position 2024 * | 27.4M | Net cash position 2025 * | 67.4M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.99
x | P/E ratio 2025 * |
-19
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 82.3% |
Managers | Title | Age | Since |
---|---|---|---|
Antoine Awad
CEO | Chief Executive Officer | 44 | 18-09-30 |
Mary Dooley
DFI | Director of Finance/CFO | 43 | 18-05-31 |
Brendan St Amant
LAW | General Counsel | - | 21-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Shea
BRD | Director/Board Member | 72 | 17-08-27 |
Peter Barrett
CHM | Chairman | 71 | 17-08-27 |
Director/Board Member | 64 | 12-09-30 |
1st Jan change | Capi. | |
---|---|---|
+19.56% | 42.68B | |
+0.48% | 42.4B | |
+45.89% | 40.04B | |
-6.20% | 28.31B | |
+6.27% | 24.94B | |
-21.50% | 18.96B | |
+30.09% | 12.3B | |
-2.39% | 11.95B | |
-4.80% | 11.55B |